Alex Sapir - 02 Feb 2026 Form 4 Insider Report for Fulcrum Therapeutics, Inc. (FULC)

Role
President & Chief Executive Officer, Director
Signature
/s/ Greg Tourangeau as attorney-in-fact for Alex Sapir
Issuer symbol
FULC
Transactions as of
02 Feb 2026
Net transactions value
$0
Form type
4
Filing time
04 Feb 2026, 16:10:02 UTC
Previous filing
28 Jan 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sapir Alex President & Chief Executive Officer, Director C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE /s/ Greg Tourangeau as attorney-in-fact for Alex Sapir 04 Feb 2026 0001709415

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FULC Stock option - Right to Buy Award $0 +650,000 $0.000000 650,000 02 Feb 2026 Common Stock 650,000 $10.72 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on February 2, 2026 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2026, subject to the reporting person's continued service on each such vesting date.

Remarks:

President & Chief Executive Officer